SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.960
+0.340 (9.39%)
At close: May 13, 2026, 4:00 PM EDT
3.900
-0.060 (-1.52%)
After-hours: May 13, 2026, 6:54 PM EDT
SAB Biotherapeutics Employees
SAB Biotherapeutics had 86 employees as of December 31, 2025. The number of employees increased by 23 or 36.51% compared to the previous year.
Employees
86
Change (1Y)
23
Growth (1Y)
36.51%
Revenue / Employee
n/a
Profits / Employee
-$109,428
Market Cap
278.29M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 86 | 23 | 36.51% |
| Dec 31, 2024 | 63 | 6 | 10.53% |
| Dec 31, 2023 | 57 | 1 | 1.79% |
| Dec 31, 2022 | 56 | -83 | -59.71% |
| Mar 31, 2022 | 148 | 62 | 72.09% |
| Dec 31, 2021 | 139 | 53 | 61.63% |
| Sep 30, 2021 | 143 | 57 | 66.28% |
| Jun 30, 2021 | 137 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fate Therapeutics | 161 |
| LENZ Therapeutics | 152 |
| Coherus Oncology | 147 |
| Voyager Therapeutics | 141 |
| Adagene | 128 |
| Foghorn Therapeutics | 106 |
| Cartesian Therapeutics | 75 |
| Cybin | 50 |
SABS News
- 1 day ago - SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright - TheFly
- 1 day ago - SAB Biotherapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 1 day ago - SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 8 days ago - SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET - GlobeNewsWire
- 14 days ago - Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics - TheFly
- 21 days ago - SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 - GlobeNewsWire
- 5 weeks ago - SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw - TheFly
- 7 weeks ago - SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire